Michael Newman
Fortune : 177 890 $ au 31/05/2026
Fortune : 177 890 $ au 31/05/2026
Michael James Newman was the founder of Decoy Biosystems, Inc., founded in 2013, where the titles held included President, CEO, CFO, Secretary & Director from 2013 to 2021.
Dr. Newman is the founder of Indaptus Therapeutics, Inc., founded in 2021, holding the title of Chief Scientific Officer since 2021.
Former jobs include Executive Director-Oncology at Novartis Pharmaceuticals Corp.
from 1992 to 1997, Senior Associate Director at Sandoz Pharmaceuticals Corp., Director & Chief Scientific Officer at Intec Pharma Ltd., Executive Vice President-Oncology at Huyabio International LLC, Faculty at Brandeis University from 1984 to 1987, Executive Vice President-Oncology at Ontogen Corp., Executive Vice President-Research & Development at Vaxiion Therapeutics LLC, and Chief Scientific Officer & Vice President-Research at Dihedron Corp.
Education includes undergraduate studies at the University of California San Diego and a doctorate from Harvard Medical School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/01/2026 | 101 074 ( 0,09% ) | 177 890 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| INDAPTUS THERAPEUTICS, INC. | Fondateur | 24/02/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
Decoy Biosystems, Inc.
Decoy Biosystems, Inc. BiotechnologyHealth Technology Develops toll-like receptor against cancer and provides cancer immunotherapy services | Directeur Général | 01/08/2021 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Corporate Officer/Principal | 01/01/1997 |
Brandeis University
Brandeis University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/1987 |
Intec Pharma Ltd.
Intec Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products to treat neurodegenerative diseases | Directeur Technique/Scientifique/R&D | - |
Huyabio International LLC
Huyabio International LLC Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 12 |
|---|---|
Huyabio International LLC
Huyabio International LLC Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
Brandeis University
Brandeis University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California San Diego
University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures medicines and provides healthcare solutions | Health Technology |
Ontogen Corp. | |
Sandoz Pharmaceuticals Corp. | |
Vaxiion Therapeutics, Inc.
Vaxiion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dihedron Corp. | |
Intec Pharma Ltd.
Intec Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products to treat neurodegenerative diseases | Health Technology |
Decoy Biosystems, Inc.
Decoy Biosystems, Inc. BiotechnologyHealth Technology Develops toll-like receptor against cancer and provides cancer immunotherapy services | Health Technology |
Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national